Immunotherapy in Bladder Cancer

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

The use of prophylactic tranexamic acid didn't lead to a reduction in blood transfusion for patients undergoing open radical cystectomy for bladder cancer.

The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.

The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk non–muscle-invasive bladder cancer.

Removing more lymph nodes during surgery may also increase the risk for death after surgery in muscle-invasive bladder cancer.